Works matching DE "VISMODEGIB"

Results: 54

Vismodegib: The first drug approved for advanced and metastatic basal cell carcinoma.

Published in:

Journal of Postgraduate Medicine, 2013, v. 59, n. 1, p. 48, doi. 10.4103/0022-3859.109494

By:

Dubey, A. K.;
Dubey, S.;
Handu, S. S.;
Qazi, M. A.

Publication type:

Article

Synthesis of Vismodegib Derivatives as Potential Smo Agonist: A Case of Undergraduate Experimental Teaching.

Published in:

Russian Journal of General Chemistry, 2023, v. 93, n. 10, p. 2694, doi. 10.1134/S1070363223100249

By:

Bao, X. F.;
Zhong, M. Y.;
Wu, Z. X.;
Zhang, Q. Y.;
Wang, L. L.;
Chen, G. L.

Publication type:

Article

Crystal structure of vismodegib, C19H14Cl2N2O3S.

Published in:

Powder Diffraction, 2023, v. 38, n. 1, p. 1, doi. 10.1017/S0885715622000446

By:

Kaduk, James A.;
Gates-Rector, Stacy;
Blanton, Thomas N.

Publication type:

Article

Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Noninterventional Cohort Study JONAS.

Published in:

Acta Dermato-Venereologica, 2022, v. 102, p. 1, doi. 10.2340/actadv.v102.293

By:

KAATZ, Martin;
MOHR, Peter;
LIVINGSTONE, Elisabeth;
WEICHENTHAL, Michael;
KREUTER, Alexander;
PFÖHLER, Claudia;
LEITER, Ulrike;
ULRICH, Jens;
UTIKAL, Jochen Sven;
GUTZMER, Ralf;
HERBST, Rudolf;
SCHADENDORF, Dirk

Publication type:

Article

9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.

Published in:

2018

By:

KIENY, Alice;
KREMER, Valérie;
SCHEIDECKER, Sophie;
LIPSKER, Dan

Publication type:

Case Study

Epidermal Cyst Formation and Hyperkeratosis in a Patient Treated with Vismodegib for Locally Advanced Basal Cell Carcinoma.

Published in:

2015

By:

Reinders, Marie G. H. C.;
Brinkhuizen, Tjinta;
Soetekouw, Patricia M. M. B.;
Kelleners-Smeets, Nicole W. J.;
Abdul Hamid, Myrurgia A.;
Mosterd, Klara

Publication type:

Case Study

Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.

Published in:

International Journal of Molecular Sciences, 2023, v. 24, n. 13, p. 10448, doi. 10.3390/ijms241310448

By:

Kleszcz, Robert;
Frąckowiak, Mikołaj;
Dorna, Dawid;
Paluszczak, Jarosław

Publication type:

Article

Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.

Published in:

International Journal of Molecular Sciences, 2018, v. 19, n. 9, p. 2485, doi. 10.3390/ijms19092485

By:

Hehlgans, Stephanie;
Booms, Patrick;
Güllülü, Ömer;
Sader, Robert;
Rödel, Claus;
Balermpas, Panagiotis;
Rödel, Franz;
Ghanaati, Shahram

Publication type:

Article

Hedgehog inhibitors with and without adjunctive therapy in treatment of locally advanced basal cell carcinoma.

Published in:

International Journal of Dermatology, 2022, v. 61, n. 1, p. 118, doi. 10.1111/ijd.15836

By:

Patel, Akash D.;
Ravichandran, Surya;
Kheterpal, Meenal

Publication type:

Article

Efficacy and safety profile of vismodegib in a real‐world setting cohort of patients with advanced basal cell carcinoma in Argentina.

Published in:

International Journal of Dermatology, 2020, v. 59, n. 5, p. 627, doi. 10.1111/ijd.14780

By:

Cozzani, Romina;
Aguila, Roxana;
Carrizo, Mariano;
Sanchez, Sergio;
Gonzalez, Abel;
Chiacchietta, A;
Alonso, C;
Ferrandini, S;
Molinari, L;
Ruiz Murineddu, E;
Del Aguila, R;
Perelli, L;
Dupertuis, M;
Valentini, J;
Diaz Alfaro, R;
Mazzuoccolo, L;
Pelati, M;
Costa, L;
Rodriguez, S;
Ferrario, D

Publication type:

Article

Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.

Published in:

International Journal of Dermatology, 2015, v. 54, n. 3, p. 370, doi. 10.1111/ijd.12543

By:

Ash, Mark M.;
Jolly, Puneet S.

Publication type:

Article

Giant morphea-form basal cell carcinoma of the umbilicus: Successful debulking with vismodegib.

Published in:

Rare Tumors, 2018, v. 10, n. 1, p. 1, doi. 10.1177/2036361318772938

By:

Robledo, Mariana Orduz;
Lebas, Eve;
Reginster, Marie-Annick;
Baghaie, Mahmoud;
Groves, Sabine;
Nikkels, Arjen F.

Publication type:

Article

Raman Spectroscopy to Monitor the Delivery of a Nano-Formulation of Vismodegib in the Skin.

Published in:

Applied Sciences (2076-3417), 2023, v. 13, n. 13, p. 7687, doi. 10.3390/app13137687

By:

Gómez, Gisela Eliane;
Calienni, María Natalia;
Alonso, Silvia del Valle;
Alvira, Fernando Carlos;
Montanari, Jorge

Publication type:

Article

Vismodegib: In Locally Advanced or Metastatic Basal Cell Carcinoma.

Published in:

2012

By:

Keating, Gillian M.

Publication type:

Journal Article

An alternative method for the preparation of vismodegib: A tool for an undergraduate laboratory course.

Published in:

Journal of Chemical Research, 2023, v. 47, n. 6, p. 1, doi. 10.1177/17475198231214490

By:

Bao, Xuefei;
Song, Chuqiao;
Liu, Dan;
Chen, Guoliang

Publication type:

Article

Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.

Published in:

Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 1, p. 193, doi. 10.1007/s00280-012-1996-6

By:

LoRusso, Patricia;
Piha-Paul, Sarina;
Mita, Monica;
Colevas, A.;
Malhi, Vikram;
Colburn, Dawn;
Yin, Ming;
Low, Jennifer;
Graham, Richard

Publication type:

Article

The Use of Noninvasive Optical Coherence Tomography to Monitor the Treatment Progress of Vismodegib and Imiquimod 5% Cream in a Transplant Patient with Advanced Basal Cell Carcinoma of the Nose.

Published in:

2016

By:

MARKOWITZ, ORIT;
SCHWARTZ, MICHELLE

Publication type:

Case Study

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.

Published in:

British Journal of Haematology, 2019, v. 185, n. 3, p. 595, doi. 10.1111/bjh.15571

By:

Bixby, Dale;
Fiedler, Walter;
Dimier, Natalie;
Simmons, Brian P.;
Riehl, Todd;
Colburn, Dawn;
Noppeney, Richard;
Lin, Tara L.;
Cortes, Jorge;
Krauter, Jürgen;
Yee, Karen;
Medeiros, Bruno C.;
Krämer, Alwin;
Assouline, Sarit

Publication type:

Article

Rational Design of Polymeric Hybrid Micelles with Highly Tunable Properties to Co-Deliver MicroRNA-34a and Vismodegib for Melanoma Therapy.

Published in:

Advanced Functional Materials, 2015, v. 25, n. 48, p. 7457, doi. 10.1002/adfm.201503115

By:

Li, Hanmei;
Fu, Yao;
Zhang, Ting;
Li, Yanping;
Hong, Xiaoyu;
Jiang, Jiayu;
Gong, Tao;
Zhang, Zhirong;
Sun, Xun

Publication type:

Article

About face: can Vismodegib change the treatment paradigm of locally advanced basal cell carcinoma?

Published in:

ANZ Journal of Surgery, 2021, v. 91, n. 6, p. 1304, doi. 10.1111/ans.16399

By:

Mansour, Kristy P.;
O'Duffy, Fergal;
Webb, Angela;
Goh, Michelle;
Morrison, Edwin

Publication type:

Article

Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face.

Published in:

Case Reports in Oncological Medicine, 2015, v. 2015, p. 1, doi. 10.1155/2015/827608

By:

Block, Alec M.;
Alite, Fiori;
Diaz, Aidnag Z.;
Borrowdale, Richard W.;
Clark, Joseph I.;
Choi, Mehee

Publication type:

Article

Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project.

Published in:

Drugs in R&D, 2017, v. 17, n. 1, p. 211, doi. 10.1007/s40268-016-0168-2

By:

Edwards, Beatrice;
Raisch, Dennis;
Saraykar, Smita;
Sun, Ming;
Hammel, Josh;
Tran, Hai;
Wehr, Nathaniel;
Arabyat, Rasha;
West, Dennis

Publication type:

Article

Vismodegib for Basal Cell Carcinoma and Beyond: What Dermatologists Need to Know.

Published in:

2022

By:

Alkeraye, Salim S.;
Alhammad, Ghadah A.;
Binkhonain, Faisal K.

Publication type:

Case Study

Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds.

Published in:

Cancer Medicine, 2015, v. 4, n. 2, p. 245, doi. 10.1002/cam4.350

By:

Yang, Hyekyung;
Cong, Wei‐na;
Yoon, Jeong Seon;
Egan, Josephine M.

Publication type:

Article

Radial shock waves prevent growth retardation caused by the clinically used drug vismodegib in ex vivo cultured bones.

Published in:

Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-69904-0

By:

Ramesh, Sowmya;
Sävendahl, Lars;
Madhuri, Vrisha;
Zaman, Farasat

Publication type:

Article

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Published in:

2017

By:

Sekulic, Aleksandar;
Migden, Michael R.;
Basset-Seguin, Nicole;
Garbe, Claus;
Gesierich, Anja;
Lao, Christopher D.;
Miller, Chris;
Mortier, Laurent;
Murrell, Dedee F.;
Hamid, Omid;
Quevedo, Jorge F.;
Hou, Jeannie;
McKenna, Edward;
Dimier, Natalie;
Williams, Sarah;
Schadendorf, Dirk;
Hauschild, Axel;
ERIVANCE BCC Investigators

Publication type:

journal article

Response to 'British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021': vismodegib and indications for its use.

Published in:

British Journal of Dermatology, 2022, v. 187, n. 5, p. 832, doi. 10.1111/bjd.21788

By:

Shariatmadari, Isla;
Matteucci, Paolo;
Barreda, Alan;
O'Toole, Lorcan

Publication type:

Article

Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy.

Published in:

2025

By:

Lambert-Swainston, Chalette;
Samlowski, Wolfram;
Reynolds, Brandon;
Hedayat, Amin

Publication type:

Case Study

Prolonged treatment response of a giant basal cell carcinoma to vismodegib after treatment cessation.

Published in:

Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 7, p. e933, doi. 10.1111/jdv.19032

By:

Carriere, Cinzia;
Polestra, Elena;
Ingannamorte, Francesca;
Pichler, Maria;
Eisendle, Klaus

Publication type:

Article

Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma – real world multicenter cohort study.

Published in:

Journal of the European Academy of Dermatology & Venereology, 2022, v. 36, n. 8, p. 1219, doi. 10.1111/jdv.18070

By:

Słowińska, M.;
Dudzisz‐Śledź, M.;
Sobczuk, P.;
Łasińska, I.;
Pietruszka, A.;
Cybulska‐Stopa, B.;
Kowalczyk, A.;
Świtaj, T.;
Czarnecka, I.;
Koseła‐Paterczyk, H.;
Rogala, P.;
Paluchowska, E.;
Składowski, K.;
Mackiewicz, J.;
Rutkowski, P.;
Owczarek, W.

Publication type:

Article

Vismodegib for periocular and orbital basal cell carcinoma.

Published in:

Current Medical Literature: Ophthalmology, 2014, v. 24, n. 1, p. 9

By:

Scawn, Richard

Publication type:

Article

Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.

Published in:

Dermatology (10188665), 2023, v. 239, n. 6, p. 868, doi. 10.1159/000531280

By:

Mannino, Maria;
Piccerillo, Alfredo;
Fabbrocini, Gabriella;
Quaglino, Pietro;
Argenziano, Giuseppe;
Dika, Emi;
Ascierto, Paolo Antonio;
Pellacani, Giovanni;
Longo, Caterina;
Fargnoli, Maria Concetta;
Bianchi, Luca;
Calzavara-Pinton, Piergiacomo;
Zalaudek, Iris;
Fava, Paolo;
Scalvenzi, Massimiliano;
Bocchino, Enrico;
Di Stefani, Alessandro;
Peris, Ketty

Publication type:

Article

Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study.

Published in:

Dermatology (10188665), 2023, v. 239, n. 5, p. 685, doi. 10.1159/000530813

By:

Ruiz-Salas, Verónica;
Podlipnik, Sebastian;
Sandoval-Clavijo, Alejandra;
Sanmartin-Jiménez, Onofre;
Bernia-Petit, Eduardo;
Bonfill-Ortí, Montserrat;
Bassas-Freixas, Patricia;
Yebenes-Marsal, Mireia;
Flórez-Menéndez, Ángeles;
Solá-Ortigosa, Joaquim;
Just-Sarobé, Miquel;
Aguayo-Ortiz, Rafael;
Masferrer i Niubó, Emili;
Quintana-Codina, Mónica;
Deza, Gustavo;
Jaka, Ane;
Fuentes, Maria José;
Cañueto, Javier;
Toll, Agustí

Publication type:

Article

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.

Published in:

Dermatology (10188665), 2023, v. 239, n. 1, p. 158, doi. 10.1159/000525612

By:

Mesti, Tanja;
Sever, Maša;
Ocvirk, Janja

Publication type:

Article

Orbito-scleral-sinus invasion of basal cell carcinoma in an immunocompromised patient on vismodegib.

Published in:

Orbit, 2021, v. 40, n. 2, p. 155, doi. 10.1080/01676830.2020.1753783

By:

Tran, Ann Q.;
Patete, Carissa L.;
Blessing, Nathan W.;
Rong, Andrew J.;
Garcia, Armando L.;
Dubovy, Sander;
Tse, David T.

Publication type:

Article

Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma.

Published in:

2018

By:

Franco, Abigail I.;
Eastwick, Gary;
Farah, Ramsay;
Heyboer, Marvin;
Lee, Mijung;
Aridgides, Paul

Publication type:

Case Study

Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma.

Published in:

Indian Dermatology Online Journal, 2013, v. 4, n. 4, p. 365, doi. 10.4103/2229-5178.120685

By:

Aditya, Suruchi;
Rattan, Aditya

Publication type:

Article

The effectiveness of vismodegib in patients with advanced periocular basal cell carcinoma: a case series of 13 patients.

Published in:

2022

By:

Villani, A.;
Costa, C.;
Cappello, M.;
Fabbrocini, G.;
Scalvenzi, M.

Publication type:

Case Study

Vismodegib (ERIVEDGE) pregnancy prevention programme: assessment of risk awareness.

Published in:

Journal of Dermatological Treatment, 2022, v. 33, n. 1, p. 466, doi. 10.1080/09546634.2020.1770166

By:

Schnetzler, Gabriel;
Cuberos, Miguel;
Bucher, Reinhard;
Stassen, Katja;
Mingrino, Roberto

Publication type:

Article

The dawn of hedgehog inhibitors: Vismodegib.

Published in:

Journal of Pharmacology & Pharmacotherapeutics, 2013, v. 4, n. 1, p. 4, doi. 10.4103/0976-500X.107628

By:

Sandhiya, Selvarajan;
Melvin, George;
Suresh Kumar, Srinivasamurthy;
Aibor Dkhar, Steven

Publication type:

Article

The Topical Nanodelivery of Vismodegib Enhances Its Skin Penetration and Performance In Vitro While Reducing Its Toxicity In Vivo.

Published in:

Pharmaceutics, 2021, v. 13, n. 2, p. 186, doi. 10.3390/pharmaceutics13020186

By:

Calienni, Maria Natalia;
Maza Vega, Daniela;
Temprana, C. Facundo;
Izquierdo, María Cecilia;
Ybarra, David E.;
Bernabeu, Ezequiel;
Moretton, Marcela;
Alvira, Fernando C.;
Chiappetta, Diego;
Alonso, Silvia del Valle;
Prieto, María Jimena;
Montanari, Jorge;
Rancan, Fiorenza

Publication type:

Article

Enhancing the Bioavailability and Efficacy of Vismodegib for the Control of Skin Cancer: In Vitro and In Vivo Studies.

Published in:

Pharmaceuticals (14248247), 2022, v. 15, n. 2, p. 126, doi. 10.3390/ph15020126

By:

Salem, Heba F.;
Gamal, Amr;
Saeed, Haitham;
Kamal, Marwa;
Tulbah, Alaa S.

Publication type:

Article

Analysis of Longitudinal‐Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2020, v. 9, n. 2, p. 96, doi. 10.1002/psp4.12487

By:

Lu, Tong;
Yang, Yujie;
Jin, Jin Y.;
Kågedal, Matts

Publication type:

Article

Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.

Published in:

Drug Discoveries & Therapeutics, 2019, v. 13, n. 2, p. 122, doi. 10.5582/ddt.2019.01020

By:

Rodríguez-Cerdeira, Carmen;
Muñoz-Garzón, Victor;
González-Cespón, José Luís

Publication type:

Article

Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series.

Published in:

Current Oncology, 2023, v. 30, n. 10, p. 9156, doi. 10.3390/curroncol30100661

By:

Wescott, Raquel;
Samlowski, Wolfram

Publication type:

Article

Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study.

Published in:

2021

By:

Verkouteren, Babette J. A.;
Wakkee, Marlies;
Reyners, An K. L.;
Nelemans, Patty;
Aarts, Maureen J. B.;
Rácz, Emőke;
Terra, Jorrit B.;
Devriese, Lot A.;
Alers, Robert-Jan;
Kapiteijn, Ellen;
van Doorn, Remco;
Bekkenk, Marcel W.;
Reinders, Marie G.H.C.;
Mosterd, Klara

Publication type:

journal article

Long‐term efficacy of a Vismodegib regime including a 1‐week drug holiday every month in two patients with Gorlin Goltz syndrome.

Published in:

Dermatologic Therapy, 2022, v. 35, n. 3, p. 1, doi. 10.1111/dth.15293

By:

Russo, Filomena;
Tognetti, Linda;
Santi, Francesco;
Lazzeri, Laura;
Rubegni, Pietro;
Taddeucci, Paolo

Publication type:

Article

Vismodegib treatment in advanced basal cell carcinomas: Real‐life experience.

Published in:

Dermatologic Therapy, 2022, v. 35, n. 1, p. 1, doi. 10.1111/dth.15195

By:

Villani, Alessia;
Fabbrocini, Gabriella;
Costa, Claudia;
Scalvenzi, Massimiliano

Publication type:

Article

Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective real‐life data.

Published in:

Dermatologic Therapy, 2021, v. 34, n. 6, p. 1, doi. 10.1111/dth.15122

By:

Gürbüz, Mustafa;
Doğan, İzzet;
Akkuş, Erman;
Ermiş, Hande;
Utkan, Güngör;
Vatansever, Sezai;
Taş, Faruk

Publication type:

Article

Sonidegib after vismodegib discontinuation in a patient with Gorlin–Goltz syndrome and multiple basal cell carcinomas.

Published in:

Dermatologic Therapy, 2021, v. 34, n. 5, p. 1, doi. 10.1111/dth.15095

By:

Piccerillo, Alfredo;
Di Stefani, Alessandro;
Costantini, Alessio;
Peris, Ketty

Publication type:

Article